Dr. Sourav Santra

Sarepta Therapeutics, USA

Associate Professor

Email: sourav.santra@gmail.com

Qualifications

2007 Ph.D., Northern Illinois University, USA

2000 M.Sc., Calcutta University, India

1998 B.Sc., Calcutta University, India

Publications (Selected)

1. “Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study”, BMJ Open (2020).
2. “Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE” BMC Neurology (2019).
3. “Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis”, CNS Drugs. (2018).
4. “Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan”, Clin Rheumatol. (2012).
5. “Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study”, Ann Rheum Dis. (2012).
6. “A Joint Model for Incomplete Data in Crossover Trials”, Journal of Statistical Planning and Inference.( 2010).
7. “One Sided Approximate Prediction Intervals for at Least p of m Observations from a Truncated Normal Population at each of r Locations” (2008). (Sankhya: The Indian Journal of Statistics, Volume 70-B, Part 2, pp. 248-266).
8. “Confidence Interval for Random-Effects Calibration Curves with Left-Censored Data.” Environmetrics Volume 20 Issue 2 (2008).
9. “Confounded cross-over designs for factorial experiments.” J. Indian Soc. Agricultural Statist. 57 (2004), Special Volume, 309-319.